Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group.
about
Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary diseaseSystemic corticosteroids for acute exacerbations of chronic obstructive pulmonary diseaseSkeletal muscle dysfunction in chronic obstructive pulmonary diseaseAction plans for COPD: strategies to manage exacerbations and improve outcomesExacerbations of COPDComparative effectiveness research in chronic obstructive pulmonary diseaseSystemic corticosteroids in acute exacerbation of COPD: a meta-analysis of controlled studies with emphasis on ICU patientsCorticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary diseaseChronic obstructive pulmonary diseasePrevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.When should acute exacerbations of COPD be treated with systemic corticosteroids and antibiotics in primary care: a systematic review of current COPD guidelinesSymptom resolution assessed using a patient directed diary card during treatment of acute exacerbations of chronic bronchitisThioredoxin-1 protects against neutrophilic inflammation and emphysema progression in a mouse model of chronic obstructive pulmonary disease exacerbationOutcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitationsCOPD exacerbations in general practice: variability in oral prednisolone courses.Effect of a 14-day course of systemic corticosteroids on the hypothalamic-pituitary-adrenal-axis in patients with acute exacerbation of chronic obstructive pulmonary diseaseCanadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 updateReadmission After COPD Exacerbation Scale: determining 30-day readmission risk for COPD patients.Human rhinovirus proteinase 2A induces TH1 and TH2 immunity in patients with chronic obstructive pulmonary diseaseTime course expression of Foxo transcription factors in skeletal muscle following corticosteroid administration.Oral corticosteroids for exacerbations of chronic obstructive pulmonary disease.Impact of an educational intervention on steroid prescribing and dosing effect on patient outcomes in COPD exacerbationsElevated placenta growth factor predicts pneumonia in patients with chronic obstructive pulmonary disease under inhaled corticosteroids therapy.Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications.Treating acute exacerbations of chronic bronchitis.Inhibition of p38 MAPK by glucocorticoids via induction of MAPK phosphatase-1 enhances nontypeable Haemophilus influenzae-induced expression of toll-like receptor 2.Exposing rodents to a combination of tobacco smoke and lipopolysaccharide results in an exaggerated inflammatory response in the lung.Chronic obstructive pulmonary disease: respiratory review of 2014.Management of acute exacerbations of chronic obstructive pulmonary disease.Predictors of early readmission among patients 40 to 64 years of age hospitalized for chronic obstructive pulmonary disease.Systemic steroids in COPD-the beauty and the beast.Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.Novel insights into the aetiology and pathophysiology of increased airway inflammation during COPD exacerbations.Risk factors for pulmonary tuberculosis in patients with chronic obstructive airway disease in Taiwan: a nationwide cohort studyTreatment of COPD exacerbations. Pharmacologic options and modification of risk factors.Necessity of amoxicillin clavulanic acid in addition to prednisolone in mild-to-moderate COPD exacerbationsManagement of an acute exacerbation of copd: are we ignoring the evidence?A history of diabetes but not hyperglycaemia during exacerbation of obstructive lung disease has impact on long-term mortality: a prospective, observational cohort study.Chronic obstructive pulmonary disease . 7: Management of COPDIncreased incidence of invasive bacterial disease in chronic obstructive pulmonary disease compared to the general population--a population based cohort study.
P2860
Q24193908-96790AFE-F70B-47AF-BEFD-3FE9927F0448Q24241135-5FAF4ED5-DA0C-4602-93E7-8867319F3CC3Q24792076-91004FBE-E13C-4437-A94E-49963DC1EAAFQ26744059-A5AC263B-F201-42F9-992A-E3729106004AQ26764891-D970A38F-3AB1-4EEF-9503-26CD96C76430Q26864606-1FCE28EE-5D14-4D09-9199-AA68A54BE027Q27010596-C480EFAC-6424-4AA7-96A8-FB88F5DEF9B3Q27023118-9FA43424-2D66-4FBC-A947-59E0F32AFD43Q27027955-D9761269-CE2E-4308-917F-9AE31721892CQ27348844-2C9B536F-ED01-4D59-966B-AAFC1F6E7A1CQ28085429-32FBEA4C-F55D-4521-9F4D-48457EF97874Q28364409-BB7F1DAC-0870-4630-877F-DA760F79BAD3Q28535004-743B7617-B788-4E64-8220-6A6B3ECDC4B5Q30480535-1003CB1C-B9BA-4243-8E62-E2DB75CA8617Q31044724-CF78113F-66CA-4B2C-95AD-1F7D92040E37Q33316582-65183E8B-91A1-4C13-926A-5C55FA66DD06Q33591899-B618B20B-1C51-422D-AA34-22B9DBB2FB7DQ33881229-0A892870-8A48-49AB-A734-8A6E5469CF11Q33898138-35004837-C16E-4FFB-B7E1-2747595DEF65Q33910776-0EECA9F3-6B77-44CB-8F8E-1F5C7B748A27Q34004412-5A470754-12B7-482C-881A-2AC056DDE303Q34021631-954ACEDB-407C-47A9-8B53-AE7EF7F81FF1Q34036358-F505DD41-4ADA-46C6-82DC-8C19798CCFA4Q34039712-89492526-9A55-4743-8CC9-D2712385C9F7Q34099576-9B0FDD18-2E28-4C6B-8250-FC4B626B742AQ34152480-E3355C33-269C-4205-9333-4B29439DACCEQ34219585-321CC3DE-F1D7-43CC-999D-5E91D8AE4142Q34440060-7049ECAE-6CF7-4E61-B2DA-2EFCE76542D4Q34445649-7BB06220-D79A-4C16-85A2-8A4E22C65AD8Q34479249-6B8E39E5-62FD-4C0F-B23B-505A32A8D3E9Q34525148-582341A1-8538-445B-A4BD-E27FE84342AEQ34550471-A346EE4F-FCFA-45A1-86BE-6396DDD40CDCQ34684239-925459F7-FF3A-4A6E-B68A-0835AABC1139Q34696165-7AB86E52-C14B-4CBC-B61D-AF060539213AQ34705590-B6F3027C-8B6D-4DCB-8371-835E61489022Q34799593-2CD273BF-7ECC-4429-B4C8-3D06D5D3C71EQ34938599-4BE616E0-C5F5-4E1A-9DE0-C24FE58AEE22Q35046902-F82438F0-6388-43A0-98AE-EDF17C41D407Q35075588-8BC98FA8-A3AA-45B9-93D2-5226F3E234CAQ35128794-73F8BFCB-070D-4688-A2B8-D8C4D8CE94AE
P2860
Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Effect of systemic glucocortic ...... fairs Cooperative Study Group.
@ast
Effect of systemic glucocortic ...... fairs Cooperative Study Group.
@en
Effect of systemic glucocortic ...... fairs Cooperative Study Group.
@nl
type
label
Effect of systemic glucocortic ...... fairs Cooperative Study Group.
@ast
Effect of systemic glucocortic ...... fairs Cooperative Study Group.
@en
Effect of systemic glucocortic ...... fairs Cooperative Study Group.
@nl
prefLabel
Effect of systemic glucocortic ...... fairs Cooperative Study Group.
@ast
Effect of systemic glucocortic ...... fairs Cooperative Study Group.
@en
Effect of systemic glucocortic ...... fairs Cooperative Study Group.
@nl
P2093
P1476
Effect of systemic glucocortic ...... fairs Cooperative Study Group.
@en
P2093
Anderson P
Deupree RH
Erbland ML
Niewoehner DE
P304
P356
10.1056/NEJM199906243402502
P407
P577
1999-06-01T00:00:00Z